Source: International Congress 2017 – "Alarming" immunological patterns in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Janeva (Skopje, FYROM (Macedonia)). IL-33 in patients with severe uncontrolled allergic asthma. 572

Member's Comments

No comment yet.

Related content which might interest you: Omalizumab in children with severe persistent allergic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Early-onset allergic severe asthma Source: International Congress 2015 – Severe asthma phenotyping Year: 2015 The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia Source: Eur Respir J 2014; 44: 239-241 Year: 2014 Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Allergic inflammation markers for earlier diagnosis of bronchial asthma in patients with allergic rhinitis Source: Annual Congress 2008 - Asthma: growing understanding of influential factors Year: 2008 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Immunotherapy in severe asthma Source: ERS webinar 2021: Immunotherapy in severe asthma Year: 2021 Heterogeneous response of airway eosinophilia to biologics in severe asthma patients Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 The march from subclinical small-airways dysfunction to asthma in children with allergic rhinitis Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Inflammatory profile of patients with allergic asthma & rhinitis versus patients with allergic rhinitis alone Source: Annual Congress 2007 - Mechanisms of inflammation in asthma and rhinitis - from cell cultures to patients Year: 2007 Iron in serum and induced sputum of patients with allergic rhinitis and allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 445s Year: 2006 Incidence of allergic asthma in patients with sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 232s Year: 2006 Zinc in serum and induced sputum of patients with allergic rhinitis and allergic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 353s Year: 2004 Treatment and outcomes in patients with asthma and allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 576s Year: 2005 Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 The evaluations of allergic rhinitis symptoms in patients with asthma and allergic rhinitis with the addiing of montelukast in asthma treatment Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004